Clinicians frequently encounter complex mood presentations where an underlying neurodegenerative process escapes prompt detection. In particular, progressive supranuclear palsy often manifests with profound emotional and executive disruptions long before classic motor signs emerge. When late-onset psychiatric symptoms resist conventional pharmacological strategies, interventional modalities such as repetitive transcranial magnetic stimulation enter the treatment pathway. However, unexpected adverse behavioral outcomes necessitate an urgent reassessment of the primary clinical diagnosis.

Neuropsychiatric Presentations of Progressive Supranuclear Palsy

Progressive supranuclear palsy is a four-repeat tauopathy classically recognized by supranuclear vertical gaze palsy, axial rigidity, and recurrent unexplained falls. However, clinicians must recognize that behavioral disturbances frequently precede these pathognomonic motor deficits by months or even years. Frontostriatal pathway degeneration drives early personality changes, severe apathy, emotional lability, and profound depressive states. Consequently, medical teams frequently misdiagnose affected patients with major depressive disorder, bipolar depression, or late-life dysthymia. Furthermore, depressive symptoms in this cohort often resist multiple standard antidepressant regimens. Because early oculomotor signs remain subtle, physicians rarely suspect a neurodegenerative etiology during initial consultations. Therefore, practitioners must maintain a high index of suspicion whenever older adults develop refractory affective disorders accompanied by subtle psychomotor slowing. Detailed neuropsychological testing often uncovers early executive impairment, which serves as an essential clue pointing toward subcortical neurodegeneration rather than primary affective illness.

The Clinical Case: From Intractable Depression to Suicidality

A recent case report documented a 56-year-old woman evaluated for severe treatment-resistant depression. Because standard pharmaceutical regimens failed to achieve remission, her clinical team initiated a course of repetitive transcranial magnetic stimulation. Shortly after receiving this neuromodulatory intervention, the patient unexpectedly exhibited severe, recurrent suicidal behavior. This acute behavioral deterioration prompted an urgent and extensive multidisciplinary medical reassessment. Comprehensive neurological examinations subsequently demonstrated subtle vertical saccadic slowing, postural instability, and axial stiffness. As a result, the clinical team established a formal diagnosis of progressive supranuclear palsy. This striking sequence emphasizes how an evolving underlying tauopathy can fundamentally alter clinical vulnerability. Furthermore, it demonstrates how challenging it is to interpret post-interventional changes when neurodegeneration remains unrecognized. The unexpected behavioral worsening underscored the volatile intersection between neuromodulatory stimulation and altered neural substrates.

Neuromodulation and Neurodegenerative Substrates

Repetitive transcranial magnetic stimulation delivers targeted magnetic pulses to modulate cortical excitability and downstream limbic connectivity. In primary major depressive disorder, prefrontal stimulation rebalances dysfunctional mood circuits and generally reduces suicidal ideation. However, applying cortical neuromodulation to an actively degenerating brain presents unique, unpredictable neurodynamic challenges. In progressive supranuclear palsy, frontostriatal disconnection already destabilizes inhibitory control mechanisms and emotional regulation. Consequently, stimulating hyper-excitable or partially denervated cortical networks might trigger paradoxical affective destabilization. Furthermore, focal stimulation may inadvertently disrupt remaining compensatory circuits within the damaged prefrontal cortex. Clinicians cannot easily determine whether the emergence of acute suicidality reflected direct neuromodulatory destabilization, unmasked underlying impulsivity, or natural neurodegenerative progression. Nevertheless, this temporal association highlights the urgent need for stringent baseline evaluations before initiating brain stimulation in atypical depressive episodes.

Frontal Dysexecutive Syndrome and Suicidal Risk

Suicide in neurodegenerative conditions frequently stems from executive dysfunction rather than classic melancholic depressive themes alone. In progressive supranuclear palsy, progressive tau accumulation rapidly destroys frontostriatal and frontolimbic loops. Consequently, patients suffer from severe loss of cognitive flexibility, defective response inhibition, and heightened behavioral impulsivity. When profound despair coexists with impaired executive control, suicidal ideation can abruptly transform into life-threatening action. Moreover, epidemiological studies confirm that suicidal and death ideation occur frequently in atypical parkinsonian disorders. However, clinicians often overlook these risks because motor deficits mask internal distress. Therefore, evaluating executive control, perseverative behaviors, and emotional dysregulation must remain central to ongoing psychiatric assessments. Recognizing this distinctive dysexecutive profile allows clinical teams to deploy strict suicide mitigation protocols before fatal consequences unfold.

Diagnostic Vigilance in Late-Onset Mood Disorders

This landmark case provides vital educational lessons for general physicians, psychiatrists, and neurologists managing refractory neuropsychiatric presentations. First, late-onset treatment-resistant depression demands comprehensive neurological screening for subtle motor and ocular abnormalities. Clinicians should specifically test vertical saccadic eye movements, postural reflexes, and axial tone during routine clinic visits. In addition, neuroimaging protocols should actively look for midbrain atrophy, including the characteristic hummingbird sign on brain magnetic resonance imaging. Second, when patients show paradoxical affective worsening or emergent impulsivity after neuromodulation, teams must immediately halt therapy and re-examine the differential diagnosis. Furthermore, multidisciplinary collaboration between psychiatry and neurology ensures timely identification of rare neurodegenerative mimics. Ultimately, thorough initial assessments prevent unnecessary invasive procedures and guide clinicians toward tailored, supportive management strategies that prioritize patient safety.

What are the earliest neuropsychiatric symptoms of progressive supranuclear palsy?

Early neuropsychiatric manifestations of progressive supranuclear palsy frequently include profound apathy, loss of initiative, irritability, emotional lability, and depressive mood states. Patients often demonstrate prominent frontal dysexecutive features, such as impaired cognitive flexibility, poor planning, and behavioral disinhibition. Because these personality and affective changes typically precede overt motor deficits like vertical gaze palsy or postural instability, clinicians often misattribute them to primary psychiatric illnesses.

Why can neuromodulation cause unexpected behavioral outcomes in neurodegenerative disorders?

Neuromodulatory techniques such as rTMS alter cortical excitability and downstream monoaminergic network connectivity. In healthy or intact brains, this modulation restores balanced limbic activity. However, in neurodegenerative conditions like progressive supranuclear palsy, pathological tau deposition disrupts frontostriatal pathways and baseline inhibitory control. Consequently, exogenous cortical stimulation can trigger paradoxical circuit dysregulation, unmask latent behavioral impulsivity, or aggravate affective destabilization.

How can clinicians distinguish primary depression from neurodegenerative mood syndromes?

Clinicians should maintain suspicion when depressive illness develops after age fifty, resists multiple therapies, or features prominent psychomotor slowing. Crucially, clinicians must examine vertical saccades, blink rates, axial rigidity, and postural stability. Detailed cognitive screening revealing disproportionate executive dysfunction also suggests an organic process. Finally, structural brain magnetic resonance imaging helps identify midbrain and frontal cortical atrophy indicative of underlying tauopathies.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. George Z et al. Severe suicidal behavior in the context of unrecognized progressive supranuclear palsy: temporal association with rTMS. Neurocase. 2026 Nov 04. doi: 10.1080/13554794.2026.2757802. PMID: 42978546.
2. Ou R, Liu H, Hou Y, et al. Suicidal and death ideation in patients with progressive supranuclear palsy and corticobasal syndrome. J Affect Disord. 2020;277:777-782.
3. Jellinger KA. Pathomechanisms of depression in progressive supranuclear palsy. J Neural Transm (Vienna). 2023;130(8):1049-1056.